Lyn Baranowski
CEO, President & DirectorMs. Lyn Baranowski serves as the Chief Executive Officer for Avalyn Pharma, Inc. since joined in October 2022 and also serves as its President and Director since October 2022. She was Director at Rani Therapeutics Holdings, Inc. from November 2021 to May 25, 2023. Ms. Baranowski served as the Chief Operating Officer of Altavant Sciences, Inc. Ms. Baranowski served as Senior Vice President of Corporate Development and Strategy at Melinta Therapeutics, Inc. since October 2013 until July 2018. Ms. Baranowski served as Vice President at Vatera Capital LLC (AKA Vatera Healthcare Partners). Ms. Baranowski served as Vice President of Business Development and Commercial Development at Pearl Therapeutics Inc. Ms. Baranowski spent with Novartis Pharmaceuticals, initially as a Senior Policy Advisor in Basel, Switzerland headquarters, where she restructured the Global Public Affairs & Communications group, managed the group's operations and worked on a variety of international public health policy initiatives with senior management and international stakeholders. Ms. Baranowski joined the Business Development & Licensing team, where she served as Director and supported numerous in-licensing deals, shaped the Respiratory/Dermatology franchise's U.S. strategy and negotiated an important co-promotion agreement. Ms. Baranowski launched a blockbuster osteoporosis drug in the U.S. market. Ms. Baranowski worked in Washington, DC and abroad for U.S. and foreign governments, focusing on international trade and investment policy issues. Her experience at the U.S. Department of Commerce includes working on a team that negotiated a trade agreement with the Russian government. Ms. Baranowski also advised U.S.-based businesses on international trade issues during her tenure at Dewey Ballantine LLP in Washington, DC. Ms. Baranowski has an M.B.A. from Harvard Business School and a B.A. in International Studies from American University.
Positions
- Company NameAvalyn Pharma Inc.Stock CodeAVLNPositionCEO, President & DirectorColleagues
- HDHeather D. TurnerIndependent Chairman
- DRDouglas R. CarlsonCFO & Chief Business Officer
- MRMelissa RhodesChief Operating Officer
- HMHoward M. LazarusChief Medical Officer
- CSCassie SaitowSenior Director of IR & Corporate Communications
- JCJill CarrollIndependent Director
- EMErin M. LavelleIndependent Director
- KHKathryn HavilandIndependent Director
